Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants https://bit.ly/42OMsfj Patients with pulmonary hypertension (PH) have been among those affected heavily by the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Early case series reported case fatality rates ranging from 19–45% in small series of 11–70 patients with PH who contracted COVID-19 [1–4]. A prospective series of 211 French patients with various forms of PH, who developed COVID-19 between February 2020 and April 2021, found an overall case fatality rate of 24.6% [5]. eng

• Schmidt, K. H.
• Milger, K.
• Pausch, C.
• Huscher, D.
• Pittrow, D.
• Grünig, E.
• Staehler, G.
• Gall, H.
• Distler, O.
• Skowasch, D.
• Halank, M.
• Wilkens, H.
• Held, M.
• Klose, H.
• Hoeper, M. M.